Trulicity (dulaglutide) superior to Lantus (insulin glargine) in East Asia study for type 2 diabetes- Eli Lilly
Once a week,Trulicity (dulaglutide) 1.5 mg and 0.75 mg, from Eli Lilly provided superior hemoglobin A1c (A1C) reduction compared to Lantus (insulin glargine) in a study of patients with type 2 diabetes and primarily enrolled from East Asia, according to new data presented by Eli Lilly and Company. The head-to-head study was presented at the 75th American Diabetes Association (ADA) Scientific Sessions in Boston.
After 26 weeks, both doses of Trulicity were superior to Lantus in A1C reduction, and significantly more patients reached the recommended A1C target of less than 7 percent. A1C reductions from baseline: -1.7 percent (Trulicity 1.5 mg), -1.32 percent (Trulicity 0.75 mg), -1.15 percent (Lantus). Percentages of patients reaching target A1C levels ( < 7 percent): 65 percent (Trulicity 1.5 mg), 54 percent (Trulicity 0.75 mg), 41 percent (Lantus). Patients treated with Trulicity 1.5 mg and 0.75 mg also lost an average of 1.51 kg and 0.88 kg respectively, while patients treated with Lantus gained 0.96 kg. Trulicity was well-tolerated in the study, showing fewer reports of hypoglycemia in patients treated with Trulicity 1.5 mg and 0.75 mg compared to Lantus. No severe hypoglycemia was reported. Other adverse events were gastrointestinal in nature, with more Trulicity-treated patients experiencing diarrhea (15.2 percent [Trulicity 1.5 mg], 8.4 percent [Trulicity 0.75 mg]) and nausea (8.7 percent [Trulicity 1.5 mg], 4.9 percent [Trulicity 0.75 mg]) compared to Lantus (1.6 percent [diarrhea] and 0.8 percent [nausea]). These results were consistent with previous Trulicity studies..
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)